摘要
目的探讨国产地西他滨(DEC)对小鼠淋巴瘤/白血病细胞EL4的体外细胞毒作用及对共刺激分子CD80表达的影响。方法小鼠淋巴瘤/白血病EL4细胞系(EL4细胞)分别用进口地西他滨(DAC)和DEC(终浓度均为0.25μM)连续体外处理3 d。采用瑞氏吉姆萨染色法观察细胞形态变化,流式细胞仪检测细胞表面共刺激分子CD80表达,CCK8法测细胞增殖抑制情况。结果 DAC和DEC均可引起EL4细胞明显的形态改变,二者作用无明显差异;DAC和DECF干预后EL4细胞CD80表达均升高,细胞增殖受抑制;二者的作用无显著差异。结论 DAC和DEC体外致EL4细胞形态改变、增殖抑制及刺激CD80表达的能力无明显差异;提示二者体内抗肿瘤作用及诱导特异性抗肿瘤免疫应答能力相近。
Objective To compare the influence of cytotoxicity and CD80 expression in EL4 cells,following in vitro treatment with decitabine（ DEC） manufactured internal. Methods EL4 cell line was treated with Dacogen（ DAC,manufactured by Xian Janssen Pharmaceutical Ltd） or DEC（ final concentration 0. 25 μmol / L） in vitro for 3 days. Morphology was analysised by method of Wright-Gimesa staining. CD80 expression was detected by method of flow cytometry. Cell proliferation was detected by method of CCK-8 kit. Results DAC and DEC treatment resulted in similar morphological changes in EL4 cells. Moreover,effects of CD80 expression and inhibited proliferation induced by both DAC and DEC in EL4 cells were no significant differences（P〉0. 05）. Conclusions There was no significant difference between DAC and DEC in the ability of change cellular morphology,inhibit proliferation and stimulate CD80 expression in mouse-lymphoma / leukemia cell EL4 cultured in vitro,which indicates the effects of the two drugs were similarity in both cytotoxic effect on tumor cells and stimulation of anti-tumor immune response when administered in vivo.
出处
《山东医药》
CAS
2014年第38期5-7,共3页
Shandong Medical Journal
基金
国家自然科学基金资助项目(81350004)
海军总医院创新培育基金项目(cxpy201302)
